Wels WS - Search Results

1

Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo.

Novak H, Noy R, Oved K, Segal D, Wels WS, Reiter Y. Novak H, et al. Among authors: wels ws. Int J Cancer. 2007 Jan 15;120(2):329-36. doi: 10.1002/ijc.22168. Int J Cancer. 2007. PMID: 17066453

2

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.

Heim C, Moser LM, Kreyenberg H, Bonig HB, Tonn T, Wels WS, Gradhand E, Ullrich E, Meister MT, Koerkamp MG, Holstege FCP, Drost J, Klusmann JH, Bader P, Merker M, Rettinger E. Heim C, et al. Among authors: wels ws. Front Immunol. 2023 Aug 18;14:1228894. doi: 10.3389/fimmu.2023.1228894. eCollection 2023. Front Immunol. 2023. PMID: 37662907 Free PMC article.

3

EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins.

Wels W, Beerli R, Hellmann P, Schmidt M, Marte BM, Kornilova ES, Hekele A, Mendelsohn J, Groner B, Hynes NE. Wels W, et al. Int J Cancer. 1995 Jan 3;60(1):137-44. doi: 10.1002/ijc.2910600120. Int J Cancer. 1995. PMID: 7814146

4

A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor.

Schmidt M, Hynes NE, Groner B, Wels W. Schmidt M, et al. Int J Cancer. 1996 Feb 8;65(4):538-46. doi: 10.1002/(SICI)1097-0215(19960208)65:4<538::AID-IJC24>3.0.CO;2-4. Int J Cancer. 1996. PMID: 8621240

5

Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera.

Hekele A, Dall P, Moritz D, Wels W, Groner B, Herrlich P, Ponta H. Hekele A, et al. Int J Cancer. 1996 Oct 9;68(2):232-8. doi: 10.1002/(SICI)1097-0215(19961009)68:2<232::AID-IJC16>3.0.CO;2-C. Int J Cancer. 1996. PMID: 8900434

6

Intra-tumoral application of a heregulin-exotoxin-a fusion protein causes rapid tumor regression without adverse systemic or local effects.

Groner B, Wick B, Jeschke M, Fiebig HH, Dengler W, Runau T, Mihatsch M, Kahl R, Schmidt M, Wels W, Stöcklin E. Groner B, et al. Int J Cancer. 1997 Mar 17;70(6):682-7. doi: 10.1002/(sici)1097-0215(19970317)70:6<682::aid-ijc10>3.0.co;2-c. Int J Cancer. 1997. PMID: 9096650

7

Targeted therapy of schwannoma cells in immunocompetent rats with an erbB2-specific antibody-toxin.

Altenschmidt U, Schmidt M, Groner B, Wels W. Altenschmidt U, et al. Int J Cancer. 1997 Sep 26;73(1):117-24. doi: 10.1002/(sici)1097-0215(19970926)73:1<117::aid-ijc18>3.0.co;2-d. Int J Cancer. 1997. PMID: 9334818

8

Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin.

Schmidt M, Reiser P, Hills D, Gullick WJ, Wels W. Schmidt M, et al. Int J Cancer. 1998 Mar 16;75(6):878-84. doi: 10.1002/(sici)1097-0215(19980316)75:6<878::aid-ijc10>3.0.co;2-#. Int J Cancer. 1998. PMID: 9506533

9

Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.

Altenschmidt U, Kahl R, Moritz D, Schnierle BS, Gerstmayer B, Wels W, Groner B. Altenschmidt U, et al. Clin Cancer Res. 1996 Jun;2(6):1001-8. Clin Cancer Res. 1996. PMID: 9816261

10

Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.

Azemar M, Schmidt M, Arlt F, Kennel P, Brandt B, Papadimitriou A, Groner B, Wels W. Azemar M, et al. Int J Cancer. 2000 Apr 15;86(2):269-75. doi: 10.1002/(sici)1097-0215(20000415)86:2<269::aid-ijc18>3.0.co;2-8. Int J Cancer. 2000. PMID: 10738256

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

153 results

Search Page

Filters